General Anesthesia Drugs Market to Surpass 7.7 Billion by 2030 Drives Due to cancer is becoming prevalent


SkyQuest projects that the general anesthesia drugs market will attain a USD 7.7 billion value by 2030, with a CAGR of 3.5% over the forecast period (2023-2030). The rising incidence of cancer is contributing to the growing demand for the global general anesthesia drugs market. As cancer becomes more prevalent, surgeries and treatments require effective anesthesia, driving the market for anesthesia drugs to ensure patient comfort and safety during procedures.

Westford,USA, Aug. 09, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, general anesthesia drugs market is being significantly influenced by the phenomenon of an ageing population. As the world’s demographic structure shifts towards older individuals, there’s a growing demand for surgeries and medical procedures, driving the need for anesthesia drugs and impacting market growth.

Browse in-depth TOC on the “General Anesthesia Drugs Market”


  • Pages – 260
  • Tables – 118
  • Figures – 77

The escalating adoption of alternative methods to general anesthesia is a pivotal driver in the global general anesthesia drugs market. Patients and healthcare professionals are exploring and embracing options like regional anesthesia and monitored anesthesia care, impacting the demand for traditional general anesthesia drugs and shaping the market landscape.

Get a sample copy of this report:

 Prominent Players in the General Anesthesia Drugs Market

  • AbbVie Inc.
  • AstraZeneca
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Hospira Inc. (Pfizer Inc.)
  • Jiangsu Nhwa Pharmaceutical Co. Ltd.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Piramal Healthcare
  • Roche Holding AG
  • Teva Pharmaceuticals
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Cardinal Health Inc.
  • Maruishi Pharmaceutical Co. Ltd.
  • Nippon Zenyaku Kogyo Co. Ltd.
  • Shandong Baolai-Leelai Bio-Tech. Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

Route of Drug Administration Segment is Expected to Grow the Market Due to their critical role in patient comfort and safety

Due to its critical role in patient comfort and safety, the “Route of Administration” stands out as a rapid growing segment in the global general anesthesia drugs market. Factors such as intravenous administration’s rapid onset and controlled titration, and inhalation anesthesia’s ease of use contribute to its significant market presence and influence.

Asia Pacific emerges as the fastest-growing segment in the global General anesthesia drugs market. The region’s increasing surgical procedures, expanding healthcare infrastructure, and rising awareness of advanced anesthesia techniques drive the demand for anesthesia drugs. This dynamic landscape positions Asia Pacific as a key player in the market’s growth trajectory.

Browse summary of the report and Complete Table of Contents (ToC):

Molecule Type Segment is Expected to Dominate the Market Due to its prominence

The molecule type segment holds a dominant position in the global General anesthesia drugs market. Varied molecule types such as intravenous agents, inhalation agents, and others are essential components, catering to diverse medical needs. This segment’s versatility significantly influences the market’s growth trajectory.

Regional markets in the North America emerges as the dominant region in the global General anesthesia drugs market. Driven by advanced healthcare infrastructure, rising surgical procedures, and technological innovations, the region showcases substantial market share. Robust investments in research and development further solidify North America’s leading position in this market.

A comprehensive analysis of the major players in the general anesthesia drugs market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavors to develop innovative solutions to cater to the growing demand.

Key Developments in the General Anesthesia Drugs Market

  • In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.
  • In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Théa SAS (Théa). Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.

Speak to Analyst for your custom requirements:

Key Questions Answered in General Anesthesia Drugs Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.
  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Surgical Drills Market

Global Liver Cancer Drugs Market

Global Wound Debridement Market

Global Asthma Spacers Market

Global Medical Mask Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.


1 Apache Way, Westford, Massachusetts 01886


USA (+1) 617-230-0741

Email: [email protected]

LinkedIn Facebook Twitter

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.